VH 3739937
Alternative Names: GSK 3739937; VH-3739937; VH-937Latest Information Update: 24 Jun 2025
At a glance
- Originator GlaxoSmithKline; ViiV Healthcare
- Developer GSK; ViiV Healthcare
- Class Antiretrovirals
- Mechanism of Action HIV replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 24 Jun 2025 Discontinued - Phase-I for HIV infections (In volunteers) in USA (PO) (GSK pipeline, June 2025)
- 24 Jun 2025 Discontinued - Phase-II for HIV infections (unspecified route) (GSK pipeline, June 2025)
- 01 Oct 2024 ViiV Healthcare suspends the phase II trial for HIV-1-infections, due to safety concerns based on preliminary findings from a related preclinical study in Argentina, Greece, Italy, Poland, Spain and USA (NCT06061081)